Physician profile

Xee Lee

Family · Fresno, CA

NPI 1831459346

$200.01

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$72.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Dexcom, INC. $31.40 2022
Dynavax Technologies Corporation $29.37 2022
Biohaven Pharmaceutical Holding Company Ltd. $24.21 2022
Novo Nordisk INC $23.55 2021
Shield Therapeutics INC $22.30 2023 Accrufer
Organon LLC $19.37 2021
Otsuka America Pharmaceutical, INC. $16.66 2023 Rexulti
Lilly USA, LLC $16.62 2023 Mounjaro
Astrazeneca Pharmaceuticals Lp $16.53 2023 Evusheld

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Xee Lee

$200.01

in general payments reported 2019-2025

Years
2021-2023
Top company
Dexcom, INC.

https://glasscript.com/doctor/10765405/xee-lee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.